Deep Bio said it signed a partnership with Visiopharm, a Danish pharmaceutical company, to supply DeepDx Prostate, its deep learning-based prostate cancer pathology image analysis software.

Under the agreement, Deep Bio will be able to expand pathologists’ access to advanced AI pathology solutions by linking DeepDx Prostate with Visiopharm’s “App Center.” The App Center provides a wide range of artificial intelligence (AI) analysis solutions that assist in the diagnosis of various cancers.